Literature DB >> 3589688

Low-dose ara-C in acute nonlymphocytic leukemia and myelodysplastic syndromes: a review of 20 years' experience.

B D Cheson, R Simon.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3589688

Source DB:  PubMed          Journal:  Semin Oncol        ISSN： 0093-7754            Impact factor:   4.929


× No keyword cloud information.
  10 in total

Review 1.  Acute myelogenous leukaemia in children.

Authors:  S O Lie
Journal:  Eur J Pediatr       Date:  1989-02       Impact factor: 3.183

2.  In vitro evidence for dose-dependent cytotoxicity as the predominant effect of low dose Ara-C on human leukemic and normal marrow cells.

Authors:  C S Chan; G P Schechter
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

3.  Myelodysplastic Syndromes in the Elderly: Treatment Options and Personalized Management.

Authors:  Sonja Burgstaller; Petra Wiesinger; Reinhard Stauder
Journal:  Drugs Aging       Date:  2015-11       Impact factor: 3.923

Review 4.  Biology and treatment of myelodysplastic syndromes--developments in the past decade.

Authors:  R Willemze; W E Fibbe; J H Falkenburg; J C Kluin-Nelemans; P M Kluin; J E Landegent
Journal:  Ann Hematol       Date:  1993-03       Impact factor: 3.673

5.  Low concentrations of cytosine arabinoside, 6-thioguanine, actinomycin-D and aclacinomycin A stimulates the differentiation of normal human marrow myeloid progenitor cells.

Authors:  H T Hassan; J K Rees
Journal:  Med Oncol Tumor Pharmacother       Date:  1989

6.  Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low dose ara-C.

Authors:  Pierre Fenaux; Norbert Gattermann; John F Seymour; Eva Hellström-Lindberg; Ghulam J Mufti; Ulrich Duehrsen; Steven D Gore; Fernando Ramos; Odile Beyne-Rauzy; Alan List; David McKenzie; Jay Backstrom; Charles L Beach
Journal:  Br J Haematol       Date:  2010-02-05       Impact factor: 6.998

7.  Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.

Authors:  Pierre Fenaux; Ghulam J Mufti; Eva Hellstrom-Lindberg; Valeria Santini; Carlo Finelli; Aristoteles Giagounidis; Robert Schoch; Norbert Gattermann; Guillermo Sanz; Alan List; Steven D Gore; John F Seymour; John M Bennett; John Byrd; Jay Backstrom; Linda Zimmerman; David McKenzie; Cl Beach; Lewis R Silverman
Journal:  Lancet Oncol       Date:  2009-02-21       Impact factor: 41.316

Review 8.  Rapid induction of complete molecular remission by sequential therapy with LDAC and sorafenib in FLT3-ITD-positive patients unfit for intensive treatment: two cases and review of the literature.

Authors:  Denise Wolleschak; Enrico Schalk; Christian Krogel; Tina M Schnoeder; Helga Luehr; Kathleen Jentsch-Ullrich; Thomas Fischer; Florian H Heidel
Journal:  J Hematol Oncol       Date:  2013-06-11       Impact factor: 17.388

9.  Phenotypic and genotypic characterization of azacitidine-sensitive and resistant SKM1 myeloid cell lines.

Authors:  Thomas Cluzeau; Alix Dubois; Arnaud Jacquel; Frederic Luciano; Aline Renneville; Claude Preudhomme; Jean Michel Karsenti; Nicolas Mounier; Pierre Rohrlich; Sophie Raynaud; Bernard Mari; Guillaume Robert; Patrick Auberger
Journal:  Oncotarget       Date:  2014-06-30

10.  Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet.

Authors:  Luca Malcovati; Eva Hellström-Lindberg; David Bowen; Lionel Adès; Jaroslav Cermak; Consuelo Del Cañizo; Matteo G Della Porta; Pierre Fenaux; Norbert Gattermann; Ulrich Germing; Joop H Jansen; Moshe Mittelman; Ghulam Mufti; Uwe Platzbecker; Guillermo F Sanz; Dominik Selleslag; Mette Skov-Holm; Reinhard Stauder; Argiris Symeonidis; Arjan A van de Loosdrecht; Theo de Witte; Mario Cazzola
Journal:  Blood       Date:  2013-08-26       Impact factor: 22.113
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.